0001437749-21-016573.txt : 20210707
0001437749-21-016573.hdr.sgml : 20210707
20210707162944
ACCESSION NUMBER: 0001437749-21-016573
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210702
FILED AS OF DATE: 20210707
DATE AS OF CHANGE: 20210707
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WEAVER GREGORY L
CENTRAL INDEX KEY: 0001251779
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35610
FILM NUMBER: 211077728
MAIL ADDRESS:
STREET 1: 185 BERRY STREET
STREET 2: SUITE 6504
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ATOSSA THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001488039
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 264753208
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 107 SPRING STREET
CITY: SEATTLE
STATE: WA
ZIP: 98104
BUSINESS PHONE: 206.588.0256
MAIL ADDRESS:
STREET 1: 107 SPRING STREET
CITY: SEATTLE
STATE: WA
ZIP: 98104
FORMER COMPANY:
FORMER CONFORMED NAME: ATOSSA GENETICS INC
DATE OF NAME CHANGE: 20100325
4
1
rdgdoc.xml
FORM 4
X0306
4
2021-07-02
0001488039
ATOSSA THERAPEUTICS, INC.
ATOS
0001251779
WEAVER GREGORY L
C/O ATOSSA THERAPEUTICS, INC.,
107 SPRING STREET
SEATTLE
WA
98104
1
Common Stock
2021-07-02
4
M
0
4581
5.64
A
4581
D
Common Stock
2021-07-02
4
M
0
45000
2.38
A
49581
D
Common Stock
2021-07-02
4
M
0
45000
2.52
A
94581
D
Common Stock
2021-07-02
4
M
0
70000
1.70
A
164581
D
Common Stock
2021-07-02
4
F
0
57084
6.40
D
107497
D
Common Stock
2021-07-02
4
S
0
107497
5.58
D
0
D
Stock Option (right to buy)
5.64
2021-07-02
4
M
0
4581
0
D
Common Stock
4581
0
D
Stock Option (right to buy)
2.38
2021-07-02
4
M
0
45000
0
D
Common Stock
45000
0
D
Stock Option (right to buy)
2.52
2021-07-02
4
M
0
45000
0
D
Common Stock
45000
0
D
Stock Option (right to buy)
1.70
2021-07-02
4
M
0
70000
0
D
Common Stock
70000
0
D
Reflects the Nasdaq closing price of the Issuer's common stock on July 01, 2021.
Reflects the weighted average sale price. The range of prices for such transaction is $5.51 to $5.65. Open market sale transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
These options were granted on May 24, 2017, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
These options were granted on June 27, 2018, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
These options were granted on May 17, 2019, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
These options were granted on May 15, 2020, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
/s/ Gregory L. Weaver
2021-07-07